Scientific and social issues of human immunodeficiency virus vaccine development.
Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.
Duke University School of Medicine, Durham, NC.
B F
BF
Haynes
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control* / Q000628:therapy*; D000818:Animals; D035841:Behavioral Research; D035843:Biomedical Research; D002986:Clinical Trials as Topic; D003906:Developing Countries; D004992:Ethics, Medical; D035082:Federal Government; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control* / Q000628:therapy*; D006679:HIV Seropositivity; D038622:Internationality; D033281:Nontherapeutic Human Experimentation; D035842:Research Subjects; D018570:Risk Assessment; D012941:Social Responsibility; D036302:Therapeutic Human Experimentation
D016915:AIDS Vaccines; D015488:HIV Antigens